FDA authorizes baricitinib alone as treatment for COVID-19


28 July 2021 - Today, the U.S. FDA revised the Emergency Use Authorisation for baricitinib (Olumiant) now authorising baricitinib alone for the treatment of COVID-19 in hospitalised adults and paediatric patients two years of age or older requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation . 

Under the revised Emergency Use Authorisation, baricitinib is no longer required to be administered with remdesivir (Veklury).

Read FDA News

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , US , COVID-19